NASDAQ:RUBY

Rubius Therapeutics News Headlines

$24.08
+1.82 (+8.18 %)
(As of 04/13/2021 10:20 AM ET)
Add
Compare
Today's Range
$21.39
Now: $24.08
$24.35
50-Day Range
$8.02
MA: $19.67
$32.01
52-Week Range
$4.20
Now: $24.08
$38.71
Volume12,442 shs
Average Volume1.75 million shs
Market Capitalization$1.96 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.37

Headlines

Rubius Therapeutics (NASDAQ RUBY) News Headlines Today

SourceHeadline
Rubius Therapeutics (NASDAQ:RUBY) Given New $40.00 Price Target at HC WainwrightRubius Therapeutics (NASDAQ:RUBY) Given New $40.00 Price Target at HC Wainwright
marketbeat.com - March 22 at 8:57 AM
Should You Take Comfort From Insider Transactions At Rubius Therapeutics, Inc. (NASDAQ:RUBY)?Should You Take Comfort From Insider Transactions At Rubius Therapeutics, Inc. (NASDAQ:RUBY)?
finance.yahoo.com - April 12 at 5:57 PM
Rubius Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of RTX-321 for the Treatment of HPV 16-Positive CancersRubius Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of RTX-321 for the Treatment of HPV 16-Positive Cancers
finance.yahoo.com - April 12 at 12:56 PM
Zacks: Analysts Expect Rubius Therapeutics, Inc. (NASDAQ:RUBY) to Post -$0.54 EPSZacks: Analysts Expect Rubius Therapeutics, Inc. (NASDAQ:RUBY) to Post -$0.54 EPS
americanbankingnews.com - April 10 at 8:08 AM
Rubius Therapeutics Presents Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors at the American Association of Cancer Research Virtual Annual MeetingRubius Therapeutics Presents Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors at the American Association of Cancer Research Virtual Annual Meeting
finance.yahoo.com - April 9 at 12:00 PM
Rubius Therapeutics (NASDAQ:RUBY) Shares Gap Up to $26.50Rubius Therapeutics (NASDAQ:RUBY) Shares Gap Up to $26.50
americanbankingnews.com - April 1 at 12:08 PM
Rubius Therapeutics (NASDAQ:RUBY) Shares Up 9.9%Rubius Therapeutics (NASDAQ:RUBY) Shares Up 9.9%
americanbankingnews.com - March 31 at 12:56 PM
Rubius Therapeutics Charts A New Path For Hard-To-Treat CancersRubius Therapeutics Charts A New Path For Hard-To-Treat Cancers
finance.yahoo.com - March 27 at 1:25 PM
Rubius Therapeutics (NASDAQ:RUBY) Shares Gap Down to $31.78Rubius Therapeutics (NASDAQ:RUBY) Shares Gap Down to $31.78
americanbankingnews.com - March 26 at 11:40 AM
Rubius Therapeutics (NASDAQ:RUBY) Price Target Raised to $40.00 at HC WainwrightRubius Therapeutics (NASDAQ:RUBY) Price Target Raised to $40.00 at HC Wainwright
americanbankingnews.com - March 22 at 10:20 AM
Rubius Therapeutics (NASDAQ:RUBY) PT Raised to $20.00Rubius Therapeutics (NASDAQ:RUBY) PT Raised to $20.00
americanbankingnews.com - March 22 at 10:20 AM
First Week of RUBY November 19th Options TradingFirst Week of RUBY November 19th Options Trading
nasdaq.com - March 19 at 7:04 PM
Implied Volatility Surging for Rubius Therapeutics (RUBY) Stock OptionsImplied Volatility Surging for Rubius Therapeutics (RUBY) Stock Options
finance.yahoo.com - March 17 at 1:34 PM
Rubius Therapeutics: Promising Cancer Treatment Data De-Risks PipelineRubius Therapeutics: Promising Cancer Treatment Data De-Risks Pipeline
finance.yahoo.com - March 17 at 8:34 AM
Rubius Therapeutics Prices Upsized Public Offering of Common StockRubius Therapeutics Prices Upsized Public Offering of Common Stock
finance.yahoo.com - March 17 at 12:39 AM
Biotech Stocks To Buy In March 2021? 4 Names To KnowBiotech Stocks To Buy In March 2021? 4 Names To Know
nasdaq.com - March 16 at 2:38 PM
Why Rubius Therapeutics Is Trading Higher TodayWhy Rubius Therapeutics Is Trading Higher Today
msn.com - March 16 at 2:38 PM
Notable Monday Option Activity: LLY, RUBY, PENNNotable Monday Option Activity: LLY, RUBY, PENN
nasdaq.com - March 15 at 6:29 PM
Rubius Therapeutics Stock Trading Higher On Positive Efficacy, Safety RTX-240 Data In Solid Tumor StudyRubius Therapeutics Stock Trading Higher On Positive Efficacy, Safety RTX-240 Data In Solid Tumor Study
finance.yahoo.com - March 15 at 6:29 PM
Why Rubius Therapeutics Stock Is Skyrocketing TodayWhy Rubius Therapeutics Stock Is Skyrocketing Today
fool.com - March 15 at 6:29 PM
Rubius Therapeutics Announces Proposed Public Offering of Common StockRubius Therapeutics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - March 15 at 6:29 PM
Rubius Rides Trial Results to Higher Stock PricesRubius Rides Trial Results to Higher Stock Prices
marketwatch.com - March 15 at 1:28 PM
This Cancer Study Is a Gamechanger, and the Stock Practically DoubledThis Cancer Study Is a Gamechanger, and the Stock Practically Doubled
247wallst.com - March 15 at 1:28 PM
Rubius Doubles on Progress in Early-Stage Cancer-Drug TrialRubius Doubles on Progress in Early-Stage Cancer-Drug Trial
finance.yahoo.com - March 15 at 1:28 PM
Rubius Stock Flies To Record High After Experimental Cancer Drug Proves ItselfRubius Stock Flies To Record High After Experimental Cancer Drug Proves Itself
finance.yahoo.com - March 15 at 1:28 PM
Rubius Therapeutics Reports Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors, Demonstrating Single-Agent ActivityRubius Therapeutics Reports Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors, Demonstrating Single-Agent Activity
finance.yahoo.com - March 15 at 7:53 AM
Rubius Therapeutics to Present Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors at the American Association of Cancer Research Virtual Annual MeetingRubius Therapeutics to Present Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors at the American Association of Cancer Research Virtual Annual Meeting
finance.yahoo.com - March 10 at 7:33 PM
Rubius Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business UpdateRubius Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
markets.businessinsider.com - February 23 at 11:05 AM
Rubius Therapeutics to Participate in the 10th Annual SVB Leerink Global Healthcare ConferenceRubius Therapeutics to Participate in the 10th Annual SVB Leerink Global Healthcare Conference
finance.yahoo.com - February 18 at 1:04 PM
Rubius Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial ResultsRubius Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results
finance.yahoo.com - February 9 at 8:57 AM
Rubius Therapeutics to Participate in Guggenheim Healthcare Talks | 2021 Oncology DaysRubius Therapeutics to Participate in Guggenheim Healthcare Talks | 2021 Oncology Days
finance.yahoo.com - February 3 at 6:39 PM
Rubius Therapeutics Provides Operational Update and Outlines 2021 Objectives  at the 39th Annual J.P. Morgan Healthcare ConferenceRubius Therapeutics Provides Operational Update and Outlines 2021 Objectives at the 39th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 11 at 5:34 PM
Rubius Therapeutics to Present at the Virtual 39th Annual J.P. Morgan Healthcare ConferenceRubius Therapeutics to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference
marketwatch.com - January 5 at 1:01 AM
Rubius Therapeutics to Present at the Virtual 39th Annual J.P. Morgan Healthcare ConferenceRubius Therapeutics to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 4 at 8:01 PM
Is Rubius (RUBY) A Good Stock To Buy Now?Is Rubius (RUBY) A Good Stock To Buy Now?
finance.yahoo.com - December 11 at 1:16 AM
Rubius Therapeutics to Participate in Evercore ISI 3rd Annual HealthCONx ConferenceRubius Therapeutics to Participate in Evercore ISI 3rd Annual HealthCONx Conference
benzinga.com - November 30 at 5:57 PM
Rubius Therapeutics to Participate in Evercore ISI 3rd Annual HealthCONx ConferenceRubius Therapeutics to Participate in Evercore ISI 3rd Annual HealthCONx Conference
finance.yahoo.com - November 30 at 5:57 PM
Rubius Therapeutics to Participate in Jefferies Virtual London Healthcare ConferenceRubius Therapeutics to Participate in Jefferies Virtual London Healthcare Conference
finance.yahoo.com - November 10 at 7:34 PM
Rubius Therapeutics Presents Preclinical Data for Lead Red Cell Therapeutic™ Clinical Oncology Program, RTX-240, at the Society for Immunotherapy of Cancer’s Annual MeetingRubius Therapeutics Presents Preclinical Data for Lead Red Cell Therapeutic™ Clinical Oncology Program, RTX-240, at the Society for Immunotherapy of Cancer’s Annual Meeting
finance.yahoo.com - November 9 at 1:16 PM
Rubius Therapeutics Reports Third Quarter 2020 Financial Results and Strong Execution Across the PipelineRubius Therapeutics Reports Third Quarter 2020 Financial Results and Strong Execution Across the Pipeline
finance.yahoo.com - November 9 at 1:16 PM
Rubius Therapeutics Announces Dosing of First Patient with Relapsed/Refractory Acute Myeloid Leukemia in the Ongoing Phase 1/2 Clinical Trial of  RTX-240Rubius Therapeutics Announces Dosing of First Patient with Relapsed/Refractory Acute Myeloid Leukemia in the Ongoing Phase 1/2 Clinical Trial of RTX-240
finance.yahoo.com - November 5 at 8:40 AM
Rubius Therapeutics to Announce Third Quarter 2020 Financial ResultsRubius Therapeutics to Announce Third Quarter 2020 Financial Results
finance.yahoo.com - October 29 at 6:58 PM
Rubius Therapeutics RTX-321 shows dual mechanism of action in HPV-positive cancersRubius Therapeutics' RTX-321 shows dual mechanism of action in HPV-positive cancers
seekingalpha.com - October 28 at 7:17 AM
Rubius Therapeutics Presents Preclinical Data for RTX-321, a Red Cell Therapeutic™ Oncology Product Candidate for HPV-Positive Cancers, Demonstrating its Dual Mechanism of ActionRubius Therapeutics Presents Preclinical Data for RTX-321, a Red Cell Therapeutic™ Oncology Product Candidate for HPV-Positive Cancers, Demonstrating its Dual Mechanism of Action
finance.yahoo.com - October 28 at 7:17 AM
Rubius Therapeutics Announces Preclinical Data Supporting its Lead Clinical Oncology Program, RTX-240, to be Presented at the Society for Immunotherapy of Cancer’s Annual MeetingRubius Therapeutics Announces Preclinical Data Supporting its Lead Clinical Oncology Program, RTX-240, to be Presented at the Society for Immunotherapy of Cancer’s Annual Meeting
finance.yahoo.com - October 22 at 11:55 PM
Are Insiders Buying Rubius Therapeutics, Inc. (NASDAQ:RUBY) Stock?Are Insiders Buying Rubius Therapeutics, Inc. (NASDAQ:RUBY) Stock?
finance.yahoo.com - October 14 at 6:13 PM
Rubius Therapeutics (RUBY) Presents at H.C. Wainwright Annual Global Investment Conference - SlideshowRubius Therapeutics (RUBY) Presents at H.C. Wainwright Annual Global Investment Conference - Slideshow
seekingalpha.com - September 18 at 7:08 PM
Rubius Therapeutics EPS beats by $0.03Rubius Therapeutics EPS beats by $0.03
seekingalpha.com - August 10 at 8:36 AM
Rubius Therapeutics Reports Second Quarter 2020 Financial Results and Positive Progress Across PipelineRubius Therapeutics Reports Second Quarter 2020 Financial Results and Positive Progress Across Pipeline
finance.yahoo.com - August 10 at 8:36 AM
Rubius Therapeutics to Announce Second Quarter 2020 Financial ResultsRubius Therapeutics to Announce Second Quarter 2020 Financial Results
finance.yahoo.com - August 3 at 8:27 PM
Did Hedge Funds Drop The Ball On Designer Brands Inc. (DBI)Did Hedge Funds Drop The Ball On Designer Brands Inc. (DBI)
finance.yahoo.com - August 3 at 3:26 PM
This page was last updated on 4/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.